Chronic lymphocytic leukemia in the recent 10 years and treatment effects of Fludarabin.

Simple item page
dc.contributor.authorKermani, Iraj Asvadien_US
dc.contributor.authorDehdilani, Mahnazen_US
dc.contributor.authorDolatkhah, Royaen_US
dc.date.accessioned2009-05-27T17:39:19Z
dc.date.available2009-05-27T17:39:19Z
dc.date.issued2007-07-28en_US
dc.descriptionAsian Pacific Journal of Cancer Prevention.en_US
dc.description.abstractOBJECTIVE: CLL (Chronic Lymphocytic Leukemia) is the most common form of leukemia in the western world and because of prolonged survival of patients, the prevalence is high. Chemotherapy is usually not indicated in early and stable disease and using Chlorambucil with or without steroids has been the drug of choice in the treatment of CLL for many years .Clinical studies have shown that using Fludarabin can cause a complete response in significant number of untreated and/or previously treated CLL patients. The aim of this study is evaluating of CLL patients and determining the effects of treatment with Fludarabin. METHODS: A retrospective (descriptive/cross sectional) study of CLL patients who admitted to Hematology and Oncology Research Center of Tabriz university of Medical Sciences, between 1995-2005 was made and 126 patients enrolled. Collection of data was carried out according to special questionnaire and response to Fludarabin was analyzed by SPSS 11 software. RESULTS: The patients mean age of diagnosis was 63.7 years (SD=8.9), 69.8% were males. Illness and fatigue were the commonest presenting symptoms in 54% and lymphadenopathy was the most common clinical sign in 88.9%.Most of the patients were in stage C in Binet system (52.4%) and/or stage IV in Rai system (44.4%).Chemotherapy with chlorambucil and Prednisolone was the most common regimen used (60.3%) and 49.2% of patients were in partial remission with this treatment. Forty two patients treated with Fludarabin and 50% were in partial remission, 35% in static disease, 10% in progressive disease and 5% in complete remission (P=0.053). CONCLUSION: The median survival with Fludarabin was 43.9 months (SD=27.2) and in the case of Chlorambucil+Prednisolone and CVP or Chop it was 45 months (SD=26.5) and 50 months (SD=32.2), respectively (P>0.05). P value in the relationship with survival and response to Fludarabin was more than 0.05.Above all, Fludarabin is the choice treatment as first and second line therapy, as well as for patients who have failed therapy with standard regimens.en_US
dc.description.affiliationHematology and Oncology Research Center, Tabriz University of Medical Sciences, Daneshgah Ave. Po Box 5166614731 Tabriz/ IR Iran. irajkermani@hotmail.comen_US
dc.identifier.citationKermani IA, Dehdilani M, Dolatkhah R. Chronic lymphocytic leukemia in the recent 10 years and treatment effects of Fludarabin. Asian Pacific Journal of Cancer Prevention. 2007 Jul-Sep; 8(3): 367-71en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/37607
dc.language.isoengen_US
dc.source.urihttps://www.apocp.orgen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshAntineoplastic Agents --adverse effectsen_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols --therapeutic useen_US
dc.subject.meshCase-Control Studiesen_US
dc.subject.meshCross-Sectional Studiesen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshIran --epidemiologyen_US
dc.subject.meshLeukemia, Lymphocytic, Chronic, B-Cell --drug therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSurvival Rateen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVidarabine --adverse effectsen_US
dc.titleChronic lymphocytic leukemia in the recent 10 years and treatment effects of Fludarabin.en_US
dc.typeComparative Studyen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Asian Pacific Journal of Cancer Prevention